Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through ...

By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting ...

Stephen D. Nimer, M.D., has been awarded the American Society of Hematology’s (ASH) Mentor Award for 2024. As director ...

Rasika Venkataraman, a third-year doctoral student working in the lab of Stanley C. Lee, PhD, at Fred Hutch Cancer Center, ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a ...

Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –– ...

Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of nuvisertib, an investigational small molecule being researched for the treatment of ...

Priothera is investigating the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in patients with ...

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation an ...